Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2010 - 2026)

Abeona Therapeutics' Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 45.43% year-over-year to $13.5 million in Q1 2026; TTM through Mar 2026 was $13.5 million, a 45.43% decrease from a year earlier, with the FY2025 full-year figure at $18.9 million, down 40.96% from the prior year.
• Other Non-Current Liabilities fell to $13.5 million in Q1 2026 per ABEO's latest filing, from $18.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $48.7 million in Q1 2024 and bottomed at $200000.0 in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $22.6 million (2025), against an average of $19.9 million.
• Across the five-year window, Other Non-Current Liabilities surged 13461.0% in 2023 and sank 95.94% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $19.7 million in 2022, then soared by 59.5% to $31.4 million in 2023, then advanced by 2.11% to $32.0 million in 2024, then plunged by 40.96% to $18.9 million in 2025, then slipped by 28.49% to $13.5 million in 2026.
• Per Business Quant, the three latest ABEO Other Non-Current Liabilities figures stand at $13.5 million (Q1 2026), $18.9 million (Q4 2025), and $22.6 million (Q3 2025).